{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:03:11Z","timestamp":1789012991614,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T00:00:00Z","timestamp":1685750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T00:00:00Z","timestamp":1685750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Sanming Project of Medicine in Shenzhen","award":["SZSM201812002"],"award-info":[{"award-number":["SZSM201812002"]}]},{"name":"the Shenzhen Key Medical Discipline Construction Fund","award":["SZGSP012"],"award-info":[{"award-number":["SZGSP012"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Systemic juvenile idiopathic arthritis (SJIA) is a chronic inflammatory disease of childhood with elevated serum IL-6 levels. As an inhibitor of IL-6R, tocilizumab (TCZ) has been approved to treat SJIA patients. TCZ-induced hypofibrinogenemia has been only reported in adult cases and limited small case series with rheumatoid arthritis or giant cell arteritis. Here, we describe the incidence of TCZ-induced hypofibrinogenemia in SJIA patients and its possible influence on bleeding risk. SJIA patients with TCZ treatment in Shenzhen Children\u2019s hospital were retrospectively reviewed. Only those with the data on serum fibrinogen levels were included. Data on clinical manifestations, laboratory parameters, management, and sJADAS10-ESR score were collected. Laboratory data were extracted following the start of TCZ therapy at 2, 4, 8, 12, and 24\u00a0weeks thereafter. Seventeen SJIA patients with TCZ treatment were included. Thirteen (76.47%, 13\/17) had hypofibrinogenemia. The lowest serum fibrinogen levels were even below 1.5\u00a0g\/L in seven (41.17%, 7\/17) patients. Among four patients without MTX treatment, two had obvious hypofibrinogenemia. Although five patients had already stopped steroid treatment 24\u00a0weeks after TCZ treatment, three of them still had hypofibrinogenemia. Only P14 had mild nasal mucosal bleeding occasionally. Coagulation tests were regularly performed in eight patients, of these, six had hypofibrinogenemia, which occurred following one to four doses of TCZ; continuation of TCZ treatment hadn\u2019t further aggravated hypofibrinogenemia. Serum fibrinogen levels were not decreased consistently with the improvement of sJADAS10-ESR score in more than half of these eight patients. Factor XIII was detected\u00a0in six patients and none was identified\u00a0with Factor XIII deficiency. TCZ alone may induce hypofibrinogenemia in SJIA patients. Continuation of TCZ treatment may be safe for most SJIA patients. But for SJIA patients with indications of surgery or complicated with MAS, the risk of hemorrhage should be regularly evaluated during TCZ treatment. The association between TCZ-induced hypofibrinogenemia and factor XIII deficiency remains uncertain.<\/jats:p><jats:p><jats:italic>Trial registration<\/jats:italic>: Not applicable; this was a retrospective study.<\/jats:p>","DOI":"10.1038\/s41598-023-36246-6","type":"journal-article","created":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T16:01:39Z","timestamp":1685808099000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Tocilizumab-induced hypofibrinogenemia in patients with systemic-onset juvenile idiopathic arthritis"],"prefix":"10.1038","volume":"13","author":[{"given":"Tingyan","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayun","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,3]]},"reference":[{"issue":"11","key":"36246_CR1","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.3928\/00904481-20121022-10","volume":"41","author":"AD Hay","year":"2012","unstructured":"Hay, A. D. & Ilowite, N. T. Systemic juvenile idiopathic arthritis: A review. Pediatr. Ann. 41(11), e232\u2013e237 (2012).","journal-title":"Pediatr. Ann."},{"issue":"4","key":"36246_CR2","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.berh.2018.02.002","volume":"31","author":"M Pardeo","year":"2017","unstructured":"Pardeo, M., Bracaglia, C. & De Benedetti, F. Systemic juvenile idiopathic arthritis: New insights into pathogenesis and cytokine directed therapies. Best Pract. Res. Clin. Rheumatol. 31(4), 505\u2013516 (2017).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"2","key":"36246_CR3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.5114\/ceji.2019.87066","volume":"44","author":"S Vilaiyuk","year":"2019","unstructured":"Vilaiyuk, S., Lerkvaleekul, B., Soponkanaporn, S., Setthaudom, C. & Buranapraditkun, S. Correlations between serum interleukin 6, serum soluble interleukin 6 receptor, and disease activity in systemic juvenile idiopathic arthritis patients treated with or without tocilizumab. Cent. Eur. J. Immunol. 44(2), 150\u2013158 (2019).","journal-title":"Cent. Eur. J. Immunol."},{"issue":"2","key":"36246_CR4","first-page":"116","volume":"37","author":"B Lerkvaleekul","year":"2019","unstructured":"Lerkvaleekul, B. & Vilaiyuk, S. Early reduction of serum interleukin-6 levels as a predictor of clinical remission in systemic juvenile idiopathic arthritis. Asian Pac. J. Allergy Immunol. 37(2), 116\u2013122 (2019).","journal-title":"Asian Pac. J. Allergy Immunol."},{"issue":"1","key":"36246_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12969-018-0224-2","volume":"16","author":"CH Hinze","year":"2018","unstructured":"Hinze, C. H. et al. Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatr. Rheumatol. J. 16(1), 7 (2018).","journal-title":"Pediatr. Rheumatol. J."},{"issue":"4","key":"36246_CR6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/art.42037","volume":"74","author":"KB Onel","year":"2022","unstructured":"Onel, K. B. et al. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: Therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 74(4), 553\u2013569 (2022).","journal-title":"Arthritis Rheumatol."},{"issue":"9","key":"36246_CR7","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1080\/21645515.2017.1316909","volume":"13","author":"M Sheppard","year":"2017","unstructured":"Sheppard, M., Laskou, F., Stapleton, P. P., Hadavi, S. & Dasgupta, B. Tocilizumab (Actemra). Hum. Vaccin Immunother. 13(9), 1972\u20131988 (2017).","journal-title":"Hum. Vaccin Immunother."},{"issue":"4","key":"36246_CR8","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/rheumatology\/kev382","volume":"55","author":"S Tarp","year":"2016","unstructured":"Tarp, S. et al. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: A systematic review and meta-analysis of randomized trials. Rheumatology (Oxford) 55(4), 669\u2013679 (2016).","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"36246_CR9","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3899\/jrheum.130690","volume":"41","author":"S Yokota","year":"2014","unstructured":"Yokota, S. et al. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. J. Rheumatol. 41(4), 759\u2013767 (2014).","journal-title":"J. Rheumatol."},{"issue":"5","key":"36246_CR10","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00296-019-04456-9","volume":"40","author":"EH Park","year":"2020","unstructured":"Park, E. H., Lee, E. Y., Shin, K. & Kim, H. A. Tocilizumab-induced anaphylaxis in patients with adult-onset still\u2019s disease and systemic juvenile idiopathic arthritis: A case-based review. Rheumatol. Int. 40(5), 791\u2013798 (2020).","journal-title":"Rheumatol. Int."},{"issue":"5","key":"36246_CR11","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jbspin.2017.02.012","volume":"84","author":"G Vitiello","year":"2017","unstructured":"Vitiello, G. et al. Sustained tocilizumab-induced hypofibrinogenemia and thrombocytopenia. Comment on: \u201cTocilizumab-induced hypofibrinogenemia: A report of 7 cases\u201d by Martis et al., Joint Bone Spine 2016, doi: 10.1016\/j.jbspin.2016.04.008. Joint Bone Spine 84(5), 649\u2013650 (2017).","journal-title":"Joint Bone Spine"},{"issue":"3","key":"36246_CR12","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jbspin.2016.04.008","volume":"84","author":"N Martis","year":"2017","unstructured":"Martis, N. et al. Tocilizumab-induced hypofibrinogenemia: A report of 7 cases. Joint Bone Spine 84(3), 369\u2013370 (2017).","journal-title":"Joint Bone Spine"},{"issue":"11","key":"36246_CR13","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/rheumatology\/keaa240","volume":"59","author":"J Tibaldi","year":"2020","unstructured":"Tibaldi, J. et al. Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis. Rheumatology (Oxford) 59(11), 3505\u20133514 (2020).","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"36246_CR14","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s12185-012-1191-x","volume":"96","author":"M Matsuoka","year":"2012","unstructured":"Matsuoka, M. et al. Hemorrhagic-acquired factor XIII deficiency associated with tocilizumab for treatment of rheumatoid arthritis. Int. J. Hematol. 96(6), 781\u2013785 (2012).","journal-title":"Int. J. Hematol."},{"issue":"8","key":"36246_CR15","doi-asserted-by":"publisher","first-page":"e69944","DOI":"10.1371\/journal.pone.0069944","volume":"8","author":"S Mokuda","year":"2013","unstructured":"Mokuda, S. et al. Tocilizumab induced acquired factor XIII deficiency in patients with rheumatoid arthritis. PLoS ONE 8(8), e69944 (2013).","journal-title":"PLoS ONE"},{"key":"36246_CR16","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.thromres.2016.02.026","volume":"140","author":"M Souri","year":"2016","unstructured":"Souri, M. et al. Non-autoimmune combined factor XIII A and B subunit deficiencies in rheumatoid arthritis patients treated with anti-interleukin-6 receptor monoclonal antibody (tocilizumab). Thromb. Res. 140, 100\u2013105 (2016).","journal-title":"Thromb. Res."},{"issue":"12","key":"36246_CR17","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1007\/s12325-019-01118-x","volume":"36","author":"R Gualtierotti","year":"2019","unstructured":"Gualtierotti, R. et al. Tocilizumab effects on coagulation factor XIII in patients with rheumatoid arthritis. Adv. Ther. 36(12), 3494\u20133502 (2019).","journal-title":"Adv. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-36246-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-36246-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-36246-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T16:02:26Z","timestamp":1685808146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-36246-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,3]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["36246"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-36246-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,3]]},"assertion":[{"value":"27 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9050"}}